Professional Essentials · Free · No registration
Sjögren’s disease
Diagnosis, gland protection, systemic manifestations and treatment decisions in Sjögren’s disease.
Sjögren’s disease is a systemic autoimmune disorder with highly variable glandular and extraglandular expression. Dryness, fatigue and pain matter, but they do not measure the same process as inflammatory arthritis, interstitial lung disease or vasculitic neuropathy. Start with three questions: how secure is the diagnosis, which manifestations are currently active, and which outcomes should treatment improve? A low systemic activity score does not make disabling symptoms unimportant; severe symptoms alone do not establish organ-threatening inflammation.
At the next visit: six decisions
- Confirm the evidence supporting the diagnosis.
- Set an eye, dental and salivary-care plan.
- Name the active organ problem and its urgency.
- Agree on a treatment target and review date.
- Separate inflammation, damage, symptoms and toxicity.
- Review reproductive plans and the status of emerging treatments.
Red flags that change the timetable
- Urgent assessment: respiratory compromise, progressive weakness, severe electrolyte disturbance or rapidly worsening kidney function.
- Prompt eye assessment: pain, photophobia or reduced vision.
- Expedited investigation: persistent focal gland enlargement, new lymphadenopathy or unexplained constitutional symptoms.
1. Build a diagnosis from complementary evidence
Document ocular and oral symptoms, recurrent gland swelling, medication exposures and systemic clues. Anticholinergic medicines, dehydration, diabetes, hepatitis C, sarcoidosis, IgG4-related disease and prior head-and-neck radiation may explain or complicate sicca. Ask about contact lenses, blepharitis and mouth breathing. Neither subjective dryness nor a positive ANA establishes Sjögren’s disease.
The 2016 ACR/EULAR classification criteria combine anti-SSA/Ro or focal lymphocytic sialadenitis on an adequate labial biopsy with objective ocular or salivary testing. They standardize research populations and support assessment; they do not replace clinical judgment. Anti-SSB/La alone is not a scored item. Anti-SSA negativity does not exclude disease, but should prompt a careful review of alternatives and the quality of objective evidence.
Use ophthalmic assessment, unstimulated salivary flow and appropriately interpreted gland imaging or biopsy to answer remaining questions. A biopsy report should establish the histological pattern and specimen adequacy, rather than merely mention inflammation. Explain residual uncertainty and what future observation could resolve it.
Diagnostic evidence and interpretation → Open demo · No registration
2. Protect eyes, teeth and remaining gland function
Treat discomfort and prevent damage in parallel. Ocular assessment distinguishes aqueous deficiency from evaporative disease, exposure and corneal injury. Artificial tears, appropriate lid care and environmental adaptation are usual starting measures; persistent surface inflammation may need ophthalmologist-directed topical therapy. Pain, photophobia or reduced vision requires timely eye assessment, rather than simply more lubricant.
For the mouth, review salivary function, mucosa, dentition, diet and swallowing. Saliva substitutes and sugar-free stimulation may help symptoms. Sjögren’s Foundation dental guidance emphasizes topical fluoride and preventive dentistry; increased salivary flow should not be assumed to eliminate caries risk. Repeated sugary or acidic drinks can undermine an otherwise helpful hydration strategy. Examine for candidiasis, painful lesions and dental infection.
A supervised trial of pilocarpine or cevimeline can be considered when useful secretory capacity remains, accounting for contraindications and local availability. Sweating and other cholinergic effects may limit use. Define a functional goal, such as eating or speaking more comfortably, and review tolerability. Persistent unilateral or focal gland enlargement needs investigation rather than automatic attribution to dryness.
October 2026 formulation update: FDA approved liquid cevimeline (EVOXAC) for adult Sjögren-related dry mouth. It offers an alternative to capsules, with the same need to assess cholinergic risks; commercial availability must be checked locally. FDA approval · Current label.
Glandular care and prevention → Open demo · No registration3. Look beyond sicca and identify the threatened organ
Establish a baseline examination and directed laboratory assessment, including blood counts, kidney function, electrolytes and urine findings. Inflammatory joint swelling, purpura, weakness, sensory loss, chronic cough and breathlessness lead to different investigations. Do not treat every new abnormality as autoimmune disease: infection, medication toxicity, vascular disease and malignancy remain alternatives.
For persistent cough or dyspnea, pulmonary guidance supports complete pulmonary function testing and HRCT. Consider airways, interstitium and pulmonary vasculature; a normal chest radiograph is insufficient to exclude ILD. Interpret declining diffusion capacity with hemoglobin, lung volumes and the clinical trajectory. Abrupt deterioration requires an acute differential, including infection and thromboembolism.
Renal tubular disease can cause hypokalemia and metabolic acidosis without a dramatic creatinine rise. Neuropathy requires localization: painful small-fiber symptoms, sensory ataxia and rapidly progressive asymmetric motor deficits are not interchangeable. Urgent specialist assessment is appropriate for progressive weakness, severe electrolyte disturbance, rapidly worsening kidney function or respiratory compromise. Establishing the lesion determines whether immune treatment, physiological correction or both are needed.
Systemic organ assessment → Open demo · No registration
4. Select systemic treatment for a defined target
Separate inflammatory arthritis from arthralgia and established mechanical disease. Confirm synovitis when joint-directed immune treatment is proposed. Likewise, neuropathic pain relief does not demonstrate control of vasculitic nerve injury, and persistent numbness may reflect damage after inflammation has settled. Record the pretreatment findings so that apparent response can be interpreted rather than inferred from the patient’s medication list.
Use EULAR’s organ-directed framework: specify the active manifestation, severity, reversibility and desired response. Local dryness care continues when systemic medication is introduced. Glucocorticoids and immunosuppressive or biologic treatments are reserved for suitable inflammatory manifestations, with intensity matched to risk. Severe disease may require multidisciplinary treatment; many organ-specific choices rely on limited direct Sjögren trial evidence.
Hydroxychloroquine is sometimes used for inflammatory musculoskeletal or cutaneous manifestations. The JOQUER trial did not demonstrate benefit on its primary dryness–pain–fatigue composite at 24 weeks. This argues against promising broad symptom relief and does not settle every distinct inflammatory indication. Apply current retinal safety monitoring when prescribing.
Before escalating for fatigue or widespread pain, assess sleep, anemia, thyroid disease, mood, deconditioning and other contributors. Rehabilitation and symptom treatment remain legitimate care. For any drug, agree on an outcome and review date; improving a laboratory marker without meaningful organ or functional benefit may be insufficient. Check infection prevention, vaccination, interactions and pregnancy compatibility.
Choosing systemic treatment → Open demo · No registration
5. Monitor change and investigate lymphoma warning features
Track inflammatory activity, accumulated damage, symptoms and treatment toxicity separately. Use comparable clinical observations across visits: walking tolerance, pulmonary physiology, neurological function, swelling, urine abnormalities or eating ability. Serial ANA or anti-SSA levels are not a universal activity monitor. Follow-up frequency should reflect organ risk and treatment, with earlier reassessment for change.
The BSR guideline highlights persistent gland enlargement, lymphadenopathy, low complement, cryoglobulinemia and monoclonal gammopathy as lymphoma-associated features. None is diagnostic alone. New persistent swelling, unexplained constitutional symptoms or changing cytopenias warrants focused investigation and suitable tissue sampling when indicated. Avoid substituting reassurance from an old scan for assessment of a new finding.
Monitoring and gland warning signs → Open demo · No registration
6. Discuss reproductive care and emerging evidence explicitly
Ask about pregnancy plans before prescribing. Anti-Ro/SSA antibodies can create fetal risk even when maternal symptoms are mild. Coordinate rheumatology and maternal–fetal medicine care. The ACR reproductive guideline conditionally recommends hydroxychloroquine in anti-Ro/La-positive pregnancy and outlines fetal surveillance; discuss uncertainty and the patient’s previous pregnancy history. Maternal disease control and medication compatibility need their own plan.
For children, recurrent parotitis may be more conspicuous than dryness. In older adults, medication burden and nutritional limitations deserve specific attention. Across ages, give the patient a short plan identifying the treating team, routine review and changes that require earlier contact.
Evidence update · 11 November 2026: NEPTUNUS now has a peer-reviewed report; OASIZ-301 has detailed congress results. UNITY was stopped for futility. NECESSITY adds preliminary combination-therapy evidence, with endpoint and safety limits. See the updated trial archive and regulatory and development map before applying a headline to an individual patient.
When discussing a new targeted therapy, distinguish mechanism, trial endpoint, clinical benefit and regional authorization. A positive systemic activity result does not establish gland regeneration or reliable fatigue relief. Offer an evidence-based discussion of suitable trials without presenting investigational approaches as proven routine treatment.
Pregnancy and special populations → Open demo · No registration
Selected sources
- 2016 ACR/EULAR classification criteria for primary Sjögren’s syndrome.
- British Society for Rheumatology guideline on adult and juvenile Sjögren disease, 2024.
- EULAR recommendations for topical and systemic therapies, 2020.
- Sjögren’s Foundation: oral management and caries prevention.
- Sjögren’s Foundation pulmonary consensus guideline, 2021.
- JOQUER randomized trial of hydroxychloroquine, 2014.
- ACR reproductive health guideline, 2020.
Evidence is linked where it changes clinical decisions. Detailed chapters retain their individual access requirements.